Antifungal Prophylaxis for Solid Organ Transplant Recipients: Seeking Clarity Amidst Controversy
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Organ transplant recipients comprise a growing and an increasingly important group of immunocompromised hosts. Between the period 1990–1993 and the period 1994–1997, the number of transplantation procedures performed in the United States alone increased 41% for liver, 81% for kidney-pancreas, 102% for pancreas, 120% for lung, and 136% for intestinal transplantations [1]. Invasive fungal infections remain one of the most significant infectious complications among organ transplant recipients. Although mycelial fungi (e.g., phaeohyphomycetes) have emerged as important pathogens within the last decade, most invasive fungal infections in these patients are due to Aspergillus and Candida [2–4]. Management of invasive mycoses, particularly aspergillus infections, has proven remarkably challenging. Antifungal prophylaxis for solid organ transplant recipients remains a complex and controversial issue. There is a striking paucity of randomized trials in the literature. Consequently, institutional practices involving antifungal prophylaxis vary widely. Nevertheless, knowledge accrued regarding epidemiology and risk factors and published data, albeit largely from cohort studies and case series, can contribute substantially toward devising rational antifungal prophylactic strategies. In this overview, I discuss the demographic characteristics and predisposing variables for fungal infections that are the pathophysiological basis for my recommendations and the approaches I outline, the disadvantages of antifungal prophylaxis, and, finally, briefly outline directions for future studies. Clinical events (e.g., augmented immunosuppression associated with high-dose corticosteroids and OKT3 monoclonal antibodies) tend to enhance the risk of invasive fungal infections, regardless of the type of solid organ transplant. However, there are risk factors sufficiently unique to account for the diversity among different types of organ transplant recipients in the incidence of fungal infections, and also in the predilection toward specific fungal pathogens, time of onset, and risk of dissemination. The frequency of invasive mycoses among organ transplant recipients and the predominant fungal pathogens are outlined in table 1. Although candidal infections are a significant complication in liver and pancreas transplant recipients, the impact of aspergillosis is greatest in the context of liver and lung transplantation. An estimated 9.3% of deaths in lung transplant recipients and 16.9% in liver recipients are due to invasive aspergillosis [3]. Liver transplant recipients. Invasive aspergillosis has been described in 1%–8% of liver transplant recipients [5, 27–30]. Aspergillus infections in liver transplant recipients are notable for their early occurrence. The median time to onset after transplantation was 17 days in one study [28] and 16 days in another [27]. In the study by Bonham et al. [31], 8 (31%) of 26 CNS lesions that occurred within 30 days of transplantation were infectious, and Aspergillus caused 6 (75%) of these lesions. In other studies, 81%–100% of the liver transplant recipients who developed invasive aspergillosis were still in the intensive care unit after transplant surgery [27–29]. Virtually all liver transplant recipients with invasive aspergillosis have had evidence of significant hepatic and/or renal dysfunction [3, 5, 29]. In a study comprising 26 proven cases of invasive aspergillosis, poor allograft function was documented in all cases; the median serum bilirubin level was 21.8 mg/dL [28]. Thrombocytopenia in liver transplant recipients is a marker of severity of hepatic dysfunction [32]. It has been proposed that platelets may play a critical role in the host defense against Aspergillus by augmenting polymorphonuclear leukocyte—mediated damage to the fungal hyphae. The nadir in posttransplantation thrombocytopenia correlated with a higher risk of invasive fungal infections in liver transplant recipients [32]. Fulminant hepatic failure, as an indication for transplantation, was associated with a higher risk of invasive fungal infections after liver transplantation [33]. Systemic fungal infections developed in 9 (21%) of 42 patients undergoing liver transplantation for acute liver failure; 5 of the fungal infections were due to Aspergillus [33]. Finally, approximately one-fourth of the cases of invasive aspergillosis have occurred after retransplantation [28]. Renal dysfunction, particularly that requiring dialysis, portends a significantly greater risk for the development of invasive aspergillosis after liver transplantation. Fifty-eight percent of the liver transplant recipients with invasive aspergillosis in one report [28] and 80% in another [27] were undergoing either hemodialysis or continuous venovenous hemofiltration prior to Aspergillus infection. Requirement of dialysis was an independently significant predictor of invasive fungal infections in a study of liver transplant recipients [34]. Therefore, alth
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grant, S. M., & Clissold, S. P. (1990) · Drugs · doi:10.2165/00003495-199039060-00006 · Cited by 661
Winston, D. J., Pakrasi, A., & Busuttil, R. W. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-10-199911160-00003 · Cited by 261 · cited 5×
“Failure to demonstrate infection due to fluconazole-resistant Candida in short-term analyses in one report [79] is not necessarily reassuring since the emergence of resistance often requires prolonged and widespread usage.”
InfluentialMenichetti, F., Del Favero, A., Martino, P., Bucaneve, G., Micozzi, A., Girmenia, C., Barbabietola, G., Pagano, L., Leoni, P., Specchia, G., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/515129 · Cited by 244
White, M. H. (1997) · Clinical Infectious Diseases · doi:10.1086/513661 · Cited by 151
Cited by
Pappas, P. G., Alexander, B. D., Andes, D. R., Hadley, S., Kauffman, C. A., Freifeld, A., Anaissie, E. J., Brumble, L. M., Herwaldt, L., Ito, J., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/651262 · Cited by 1,570
Aspergillus Infections in Transplant Recipients
Singh, N., & Paterson, D. L. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.44-69.2005 · Cited by 579
Self-citationHusain, S., Wagener, M. M., & Singh, N. (2001) · Emerging Infectious Diseases · doi:10.3201/eid0703.010302 · Cited by 405
Self-citationInvasive Aspergillosis: Epidemiology, Diagnosis and Management in Immunocompromised Patients
Maschmeyer, G., Haas, A., & Cornely, O. A. (2007) · Drugs · doi:10.2165/00003495-200767110-00004 · Cited by 366
Minari, A., Husni, R., Avery, R. K., Longworth, D. L., DeCamp, M., Bertin, M., Schilz, R., Smedira, N., Haug, M. T., Mehta, A., et al. (2002) · Transplant Infectious Disease · doi:10.1034/j.1399-3062.2002.t01-2-02002.x · Cited by 351
Metadata
- Authors
- Singh, N.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-08-01
- Volume
- 31
- Issue
- 2
- Pages
- 545-553
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W1976927311
- Cited by
- 140
- References
- 4
- FWCI
- 6.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antifungal Prophylaxis for Solid Organ Transplant Recipients: Seeking Clarity Amidst Controversy. https://app.cochat.ai/papers/10.1086/313943
- The paper
- Singh, N. (2000). Antifungal Prophylaxis for Solid Organ Transplant Recipients: Seeking Clarity Amidst Controversy. Clinical Infectious Diseases. https://doi.org/10.1086/313943
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.